U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C17H26N4O
Molecular Weight 302.4145
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMEDASTINE

SMILES

CCOCCN1C(=NC2=C1C=CC=C2)N3CCCN(C)CC3

InChI

InChIKey=KBUZBQVCBVDWKX-UHFFFAOYSA-N
InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C17H26N4O
Molecular Weight 302.4145
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Emedastine is an antihistaminic agent, which was approved by FDA for the treatment of allergic conjunctivitis (Emadine brand name). The drug acts selectively on H1 receptors with lower affinity to H2 and H3 subtypes. Emedastine has a relatively unfavorable CNS effect profile. A small percentage of patients reported somnolence as an adverse effect after administration.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.3 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
EMADINE

Cmax

ValueDoseCo-administeredAnalytePopulation
2 ng/mL
2 mg single, oral
EMEDASTINE plasma
Homo sapiens
2.9 ng/mL
2 mg single, oral
EMEDASTINE plasma
Homo sapiens
4 ng/mL
2 mg 2 times / day steady-state, oral
EMEDASTINE plasma
Homo sapiens
6 ng/mL
2 mg 2 times / day steady-state, oral
EMEDASTINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
16.9 ng × h/mL
2 mg single, oral
EMEDASTINE plasma
Homo sapiens
29.7 ng × h/mL
2 mg single, oral
EMEDASTINE plasma
Homo sapiens
24.4 ng × h/mL
2 mg 2 times / day steady-state, oral
EMEDASTINE plasma
Homo sapiens
46.4 ng × h/mL
2 mg 2 times / day steady-state, oral
EMEDASTINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
6.4 h
2 mg single, oral
EMEDASTINE plasma
Homo sapiens
10.1 h
2 mg single, oral
EMEDASTINE plasma
Homo sapiens
6.6 h
2 mg 2 times / day steady-state, oral
EMEDASTINE plasma
Homo sapiens
9.1 h
2 mg 2 times / day steady-state, oral
EMEDASTINE plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dose is one drop (0.05% solution) in the effected eye up to four times daily.
Route of Administration: Other
In Vitro Use Guide
Human trabecular meshwork cells were treated with emedastine and at concentration of 1.44 nM the drug antagonized histamine-induced phosphoinositide turnover by 50%.
Substance Class Chemical
Record UNII
9J1H7Y9OJV
Record Status Validated (UNII)
Record Version